Willcocks A L, Nahorski S R
Biochem Pharmacol. 1983 Nov 15;32(22):3311-9. doi: 10.1016/0006-2952(83)90356-8.
The binding characteristics of the radio-iodinated beta-adrenoceptor antagonist ligand 125I-iodohydroxybenzylpindolol (125I-IHYP) have been compared in membrane preparations derived from three different sources in a single mammalian species. In membrane preparations derived from rat lung and erythrocytes, 125I-IHYP binds solely to beta-adrenoceptors as defined by the stereoselectivity of the isomers of propranolol and the affinity of isoprenaline. However, in membranes prepared from rat cerebral cortex, although some 30% of 125I-HYP binding is to beta-adrenoceptors, a large proportion of the remainder is to sites that exhibit characteristics for 5-hydroxytryptamine (5HT) recognition. Thus, binding assays for 125I-IHYP in cerebral cortical membranes performed in the presence of 30 microM (-)-isoprenaline (to eliminate the binding of the ligand to beta-adrenoceptors) show that isomers of propranolol still maintain a degree of stereoselectivity at these sites. Also, 5HT and its congeners exhibit binding activity similar to that seen at 5HT receptors identified by 3H-5HT.
在单一哺乳动物体内,从三种不同来源获取的膜制剂中,对放射性碘化β-肾上腺素能受体拮抗剂配体125I-碘羟基苄基吲哚洛尔(125I-IHYP)的结合特性进行了比较。在源自大鼠肺和红细胞的膜制剂中,根据普萘洛尔异构体的立体选择性和异丙肾上腺素的亲和力来定义,125I-IHYP仅与β-肾上腺素能受体结合。然而,在由大鼠大脑皮层制备的膜中,虽然约30%的125I-HYP结合到β-肾上腺素能受体上,但其余大部分结合到表现出5-羟色胺(5HT)识别特征的位点。因此,在30微摩尔(-)-异丙肾上腺素存在下(以消除配体与β-肾上腺素能受体的结合)对大脑皮层膜中125I-IHYP进行的结合测定表明,普萘洛尔异构体在这些位点仍保持一定程度的立体选择性。此外,5HT及其同系物表现出与通过3H-5HT鉴定的5HT受体相似的结合活性。